May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Correlation of Self–reported and Measured Visual Function and Mobility Changes in Recipients of the ASR® device
Author Affiliations & Notes
  • G. Dagnelie
    Ophthalmology, Johns Hopkins Univ SoM, Baltimore, MD
  • R.W. Massof
    Ophthalmology, Johns Hopkins Univ SoM, Baltimore, MD
  • K.A. Turano
    Ophthalmology, Johns Hopkins Univ SoM, Baltimore, MD
  • ASR Study Group
    Ophthalmology, Johns Hopkins Univ SoM, Baltimore, MD
  • A.K. Kiser
    Ophthalmology, Johns Hopkins Univ SoM, Baltimore, MD
  • R.A. Schuchard
    Rehab R&D Ctr, VAMC and Emory Univ, Decatur, GA
  • J.S. Pollack
    Ophthalmology, Rush Univ Med Ctr, Chicago, IL
  • Footnotes
    Commercial Relationships  G. Dagnelie, Optobionics Corp., F; R.W. Massof, None; K.A. Turano, None; A.K. Kiser, Optobionics Corp., F; R.A. Schuchard, Optobionics Corp., F; J.S. Pollack, Optobionics Corp., F.
  • Footnotes
    Support  Optobionics Corp.
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5682. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Dagnelie, R.W. Massof, K.A. Turano, ASR Study Group, A.K. Kiser, R.A. Schuchard, J.S. Pollack; Correlation of Self–reported and Measured Visual Function and Mobility Changes in Recipients of the ASR® device . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5682.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To examine the level of agreement between measured visual function and mobility in the laboratory and subjects’ self–reported visual performance, through interviews as well as through validated visual function (VALVVFQ–54) and mobility (Turano) questionnaires, in RP patient recipients of the Optobionics Artificial Silicon RetinaTM device.

Methods: : Subjects were tested in the laboratory on multiple visual function (VF) dimensions, and their orientation and mobility (O&M) was rated by experienced O&M instructors. A self–rating interview was administered for similar dimensions of VF and O&M, and the two calibrated questionnaires were administered; questionnaire scores were transformed to person measures based on item weights derived for comparable populations (RP/glaucoma; VF, Stelmack, IOVS 45:3919–28; mobility, Turano, IOVS 43:2874–81). All measures were taken pre–op and at 3 and 6 months post–op. Change was defined as scores exceeding the 95% confidence interval for the test (per individual if available) for VF; changes in bumps and timing for O&M; any increase or decrease reported in interviews; and person measure scores exceeding 2.78× StdErr (established by Stelmack and Turano, respectively) on the questionnaires.

Results: : By 6 months post–op, 10 of 20 subjects rated brightness, contrast, color, movement and shape perception, and resolution as improved in the operated eye, while 3 reported deteriorations; in the fellow eye, 4 and 6 subjects reported improvements and deteriorations, respectively. Changes in person measure for the VALVVFQ–54 showed non–significant correlations with these ratings: +0.10 for the operated eye, –0.11 for the fellow eye. These person measures did, however, correlate marginally significantly with a compound subject VF score representing the net percentage of VF tests showing significant improvements in the operative eye: r=0.44 (p=.06). A similar, though not significant relationship was found between person measures for the mobility questionnaire and observed O&M performance.

Conclusions: : Based on the 3– and 6–month post–op results, the two self–report questionnaires used are a better indicator for measurable changes in visual function than they are for interview ratings, or than the interview ratings are for measurable function. Twelve month post–op data, available by March 2006, will be included in an updated analysis to be presented at the meeting.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • retinal degenerations: hereditary • low vision 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.